Proton pump inhibitors: the beginning of the end or the end of the beginning?

Current Opinion in Pharmacology

Volumn 8, Issue 6, 2008, Pages 677-684

  Scarpignato, Carmelo ^a   Hunt, Richard H ^b  

^a Laboratory of Clinical Pharmacology   (Italy)

^b Division of Gastroenterology   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

8 (2,6 DIMETHYLBENZYLAMINO) N (2 HYDROXYETHYL) 2,3 DIMETHYLIMIDAZO[1,2 A]PYRIDINE 6 CARBOXAMIDE; ADENOSINE TRIPHOSPHATASE (POTASSIUM) INHIBITOR; ADENOSINE TRIPHOSPHATASE INHIBITOR; AGI 010; AGN 201904Z; BENATOPRAZOLE; BENZIMIDAZOLE DERIVATIVE; BICARBONATE; CS 526; DEXLANSOPRAZOLE; ESOMEPRAZOLE; FAMOTIDINE; GASTROINTESTINAL AGENT; GELATIN; HISTAMINE H2 RECEPTOR ANTAGONIST; ILAPRAZOLE; LANSOPRAZOLE; LONG ACTING DRUG; NITRIC OXIDE DONOR; NMI 826; OMEPRAZOLE; OX 17; PANTOPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; REVAPRAZAN; SORAPRAZAN; STOMACH SECRETION INHIBITOR; TAK 390MR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VECAM;

AREA UNDER THE CURVE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED RELEASE FORMULATION; DELAYED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; EVENING DOSAGE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HEARTBURN; HUMAN; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; NONHUMAN; PATENT; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER GASTROINTESTINAL TRACT;

ANIMALS; BINDING, COMPETITIVE; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; MOLECULAR STRUCTURE; PROTON PUMP INHIBITORS; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 55649094423     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.09.004     Document Type: Review

References (52)

1. Modlin I.M., Sachs G., Wright N., and Kidd M. Edkins and a century of acid suppression. Digestion 72 (2005) 129-145. Excellent historical review summarizing the key achievements in the physiology and pharmacology of gastric acid secretion.
2. Scarpignato C., Pelosini I., and Di Mario F. Acid suppression therapy: where do we go from here?. Dig Dis 24 (2005) 7-42. Comprehensive review on future developments in the field of antisecretory drugs.
3. Marshall B.J., and Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1 (1984) 1311-1315. Seminal paper suggesting the etiological role of Helicobacter pylori in peptic ulcer disease.
4. Tytgat G.N. Are there unmet needs in acid suppression?. Best Pract Res Clin Gastroenterol 18 Suppl (2004) 67-72. Thoughtful review first addressing the unmet clinical needs in acid-related diseases.
5. Hunt R.H. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther 22 Suppl 3 (2005) 10-19
6. Yuan Y., Wang C.C., Yuan Y.-H., and Hunt R.H. The proportion of patients who are free of reflux symptoms during the initial days of treatment with proton pump inhibitors (PPIs) in GERD trials: a meta-analysis. Gastroenterology 134 Suppl 1 (2008) A-174 [Abstract#S1085]
7. Katz P.O., Scheiman J.M., and Barkun A.N. Review article: acid-related disease - what are the unmet clinical needs?. Aliment Pharmacol Ther 23 Suppl 2 (2006) 9-22
8. Chey W.D., Mody R., Kothari S., Wu E., Chen L., Persson B., Beaulieu N., and Lu M. Are proton pump inhibitors (PPIs) sufficient in controlling symptoms of gastro-esophageal reflux disease (GERD)? a community-based US survey study. Gastroenterology 134 Suppl 1 (2008) A-325 [Abstract#M1041]
9. Tutuian R., Katz P.O., and Castell D.O. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol 16 (2004) 441-443
10. Orr W.C., Allen M.L., and Robinson M. The pattern of nocturnal and diurnal esophageal acid exposure in the pathogenesis of erosive mucosal damage. Am J Gastroenterol 89 (1994) 509-512
11. Orr W.C. Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management. Eur J Gastroenterol Hepatol 17 (2005) 113-120
12. Wang C., and Hunt RH. The precise role of acid in non-erosive reflux disease (NERD). Digestion 78 Suppl. 1 (2008) 31-41
13. Rackoff A., Agrawal A., Hila A., Mainie I., Tutuian R., and Castell D.O. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus 18 (2005) 370-373
14. 2-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol 15 (2001) 355-370
15. Hunt R.H. Importance of pH control in the management of GERD. Arch Intern Med 159 (1999) 649-657. Comprehensive review summarizing the current understanding of the role of acid suppression in the management of GERD.
16. Scarpignato C., and Pelosini I. Review article: the opportunities and benefits of extended acid suppression. Aliment Pharmacol Ther 23 Suppl 2 (2006) 23-34. A thorough discussion on the potential clinical benefits of new long-acting PPIs.
17. Tytgat G.N. Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol 13 Suppl 1 (2001) S29-S33. Critical paper addressing the limitations of current antisecretory regimens.
18. Pezanoski J., Guanaratnam N., and Cowen M. Correct and incorrect dosing of proton pump inhibitors and its impact on GERD symptoms. Gastroenterology 124 Suppl 1 (2003) A228
19. Chey W.D., Inadomi J.M., Booher A.M., Sharma V.K., Fendrick A.M., and Howden C.W. Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol 100 (2005) 1237-1242
20. Andersson K., and Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 108 (2005) 294-307. Comprehensive review on a new class of drugs targeting the proton pump.
21. Parsons M.E., and Garner A. Review article: drug development in gastroenterology - the changing view of industry. Aliment Pharmacol Ther 9 (1995) 457-463
22. Data Monitor. Pipeline Insight: Upper GI Disorders. 2007;1-226 Interesting perspective on what is going on in the field of GI drug development.
23. Mayer M.D., Vakily M., Witt G., and Mulford D.J. The pharmacokinetics of TAK-390MR 60 mg, a dual delayed release formulation of the proton pump inhibitor TAK-390, and Lansoprazole 60 mg: a retrospective analysis. Gastroenterology 134 Suppl 1 (2008) A-176 [Abstract#s1095]
24. Zhang W., Wu J.-T., and Atkinson S. Pharmacokinetic (PK), pharmacodynamic (PD), and safety of single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified release TAK-390 (TAK-390MR) and 30 mg oral doses of lansoprazole (Lan) in healthy subjects. Gastroenterology 132 Suppl 2 (2007) A-487 [Abstract#T1194]
25. Sharma P., Shaheen N.J., Perez M.C., Pilmer B., Lee M., and Peura D.A. TAK-390MR, a proton pump inhibitor (PPI) with a novel dual delayed release (DDR) formulation, is highly effective in the healing of erosive esophagitis (EE): data from two randomized controlled trials. Gastroenterology 134 Suppl 1 (2008) A-171 [Abstract#S1073]
26. Metz D.C., Howden C.W., Perez M.C., Larsen L.M., and O'Neil J.M. TAK-390MR, a proton pump inhibitor (PPI) with a novel dual delayed release formulation, maintains healing and controls heartburn in GERD patients with healed erosive esophagitis. Gastroenterology 134 Suppl 1 (2008) A-171 [Abstract#S1074]
27. Howden C.W. Review article: immediate-release proton-pump inhibitor therapy - potential advantages. Aliment Pharmacol Ther 22 Suppl 3 (2005) 25-30
28. Howden CW, Ballard ED, Koch FK, Gautille TC, Bagin RG: Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD. J Clin Gastroenterol 2008, in press.
29. Katz P.O., Koch F.K., Ballard E.D., Bagin R.G., Gautille T.C., Checani G.C., Hogan D.L., and Pratha V.S. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther 25 (2007) 197-205
30. Chowers Y., Atarot T., Kostadinov A., Nudelman M., Bar-Peled O., Brenman L., Pankratov O., and Naveh M. PPI activity is optimized by VB101, a parietal cell activator. Gastroenterology 134 Suppl 1 (2008) A-172 [Abstract#s1076]
31. Hunt R.H., Armstrong D., Yaghoobi M., James C., Chen Y., Leonard J., Shin J.M., Lee E., Tang-Liu D., and Sachs G. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 28 (2008) 187-199. First human pharmacodynamic and pharmacokinetic study with a PPI prodrug.
32. +-ATPase in vitro and in vivo. Biochem Pharmacol 71 (2006) 837-849. Excellent biochemical and pharmacological characterization of a novel chemical entity targeting the proton pump.
33. Galmiche J.P., Bruley Des Varannes S., Ducrotte P., Sacher-Huvelin S., Vavasseur F., Taccoen A., Fiorentini P., and Homerin M. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 19 (2004) 655-662
34. Hunt R.H., Armstrong D., James C., Chowdhury S.K., Yuan Y., Fiorentini P., Taccoen A., and Cohen P. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol 100 (2005) 1949-1956
35. Hunt R.H., Armstrong D., Yaghoobi M., James C., and Chen Y. S-tenatoprazole-Na 30 mg, 60 mg and 90 mg versus esomeprazole (ESO) 40 mg in healthy male volunteers (HMVs). Gastroenterology 132 Suppl 2 (2007) A-488 [Abstract#T1201]
36. Yuan Y., Chen Y., and Hunt R.H. Dose-effect of S-tenatoprazole-Na in healthy volunteers: a meta-analysis of individual subject data from four pharmacodynamic studies. Gastroenterology 134 Suppl 1 (2008) A-176 [Abstract#S1093]. Meta-analysis showing the pharmacodynamic superiority of S-tenatoprazole sodium over the current PPI regimens.
37. Junghard O., Hassan-Alin M., and Hasselgren G. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur J Clin Pharmacol 58 (2002) 453-458
38. Miner Jr. P.B., Katz P.O., Chen Y., and Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 98 (2003) 2616-2620
39. Chiesa V, Palmer A, Brehm Ch, Grundler G, Senn-Bilfinger J, Simon W, Postius S, Kromer W [Altana Pharma]: 4-substituted benzimidazoles and their use as inhibitors of gastric secretion. WO 2004/054984-A1.
40. +-ATPase. Biochem Pharmacol 73 (2007) 198-205
41. Ito K., Kinoshita K., Tomizawa A., Inaba F., Morikawa-Inomata Y., Makino M., Tabata K., and Shibakawa N. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo [2,3-d]pyridazine (CS-526). J Pharmacol Exp Ther 323 (2007) 308-317
42. Ito K., Kinoshita K., Tomizawa A., Morikawa-Inomata Y., Inaba F., Fujita Y., Tabata K., and Shibakawa N. The effect of subchronic administration of 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2 methylcyclopropyl] methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526), a novel acid pump antagonist, on gastric acid secretion and gastrin levels in rats. J Pharmacol Exp Ther 326 (2008) 163-170
43. Simon W.A., Herrmann M., Klein T., Shin J.M., Huber R., Senn-Bilfinger J., and Postius S. Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther 321 (2007) 866-874
44. Kahrilas P.J., Dent J., Lauritsen K., Malfertheiner P., Denison H., Franzén S., and Hasselgren G. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 5 (2007) 1385-1391. First published clinical study with a P-CAB.
45. Dent J., Kahrilas P.J., Hatlebakk J., Vakil N., Denison H., Franzén S., and Lundborg P. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 103 (2008) 20-26
46. 2-receptor antagonists in the era of proton pump inhibitors. In: Lundell L. (Ed). Guidelines for Management of Symptomatic Gastro-oesophageal Reflux Disease (1998), Science Press 55-66
47. 2-receptor antagonist. WO 2004/37256.
48. Fandriks L., Lonroth H., Pettersson A., and Vakil N. Can famotidine and omeprazole be combined on a once-daily basis?. Scand J Gastroenterol 42 (2007) 689-694
49. Wallace J.L., and Miller M.J. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology 119 (2000) 512-520
50. Saha J.K., Wang T., Stewart R., Trocha M., Shumway M., Garvey D., Letts L.G., Wolfe M.M., and Tam S.W. Enhanced gastroprotective and anti-ulcerogenic activities in rats of a new class of proton pump inhibitor containing nitrosothiol nitric oxide donor. Gastroenterology 120 Suppl 1 (2001) A144-A145 [Abstract# 772]
51. Sorba G., Galli U., Cena C., Fruttero R., Gasco A., Morini G., Adami M., Coruzzi G., Brenciaglia M.I., and Dubini F. A new furoxan NO-donor rabeprazole derivative and related compounds. Chembiochem 4 (2003) 899-903
52. Yuan Y., and Hunt R.H. Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: evidence of an unmet need?. Am J Gastroenterol 103 Suppl. 1 (2008) S50. Systematic review showing that in patients with pathological nocturnal reflux twice daily DR-PPIs may still not adequately control nighttime acidity.